Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial von Tauber, E, MD, Kollaritsch, H, MD, Korinek, M, MD, Rendi-Wagner, P, MD, Jilma, B, Dr, Firbas, C, MD, Schranz, S, MD, Jong, E, MD, Klingler, A, PhD, Dewasthaly, S, MD, Klade, CS, PhD

Volltext

Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age von Kaltenböck, A, Dubischar-Kastner, K, Schuller, E, Datla, Mahima, Klade, C.S, Kishore, T.S.A

Volltext

Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073 von Fytili, P, Dalekos, G.N, Schlaphoff, V, Suneetha, P.V, Sarrazin, C, Zauner, W, Zachou, K, Berg, T, Manns, M.P, Klade, C.S, Cornberg, M, Wedemeyer, H

Volltext

Hepatitis C virus-specific T cell responses against conserved regions in recovered patients von Klade, C.S, Kubitschke, A, Stauber, R.E, Meyer, M.F, Zinke, S, Wiegand, J, Zauner, W, Aslan, N, Lehmann, M, Cornberg, M, Manns, M.P, Reisner, P, Wedemeyer, H

Volltext

Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis von Vytvytska, Oresta, Nagy, Eszter, Blüggel, Martin, Meyer, Helmut E., Kurzbauer, Robert, Huber, Lukas A., Klade, Christoph S.

Volltext

Identification of tumor antigens in renal cell carcinoma by serological proteome analysis von Klade, Christoph S., Voss, Tilman, Krystek, Edeltraud, Ahorn, Horst, Zatloukal, Kurt, Pummer, Karl, Adolf, Günther R.

Volltext

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine : a non-inferiority, phase III , randomised controlled trial. Commentary von FISCHER, Marc, CASEY, Christine, JONG, E, KLINGLER, A, DEWASTHALY, S, KLADE, C. S, CHEN, Robert T, TAUBER, E, KOLLARITSCH, H, KORINEK, M, RENDI-WAGNER, P, JILMA, B, FIRBAS, C, SCHRANZ, S

Volltext

Identification and characterization of 9D7, a novel human protein overexpressed in renal cell carcinoma von Klade, Christoph S., Dohnal, Alexander, Fürst, Walter, Sommergruber, Wolfgang, Heider, Karl‐Heinz, Gharwan, Helen, Ratschek, Manfred, Adolf, Günther R.

Volltext

Klade CS, Dohnal A, Furst W, Sommergruber W, Heider KH, Gharwan H, Ratschek M, Adolf GR. Identification and characterization of 9D7, a novel human protein overexpressed in renal ce... von Klade, CS, Dohnal, A, Furst, W, Sommergruber, W, Heider, KH, Gharwan, H, Ratschek, M, Adolf, GR

Volltext

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b von Kiladjian, Jean-Jacques, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Gisslinger, Heinz

Volltext

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera von Gisslinger, Heinz, Zagrijtschuk, Oleh, Buxhofer-Ausch, Veronika, Thaler, Josef, Schloegl, Ernst, Gastl, Guenther A., Wolf, Dominik, Kralovics, Robert, Gisslinger, Bettina, Strecker, Karin, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Schalling, Martin, Them, Nicole C., Kadlecova, Pavla, Klade, Christoph, Greil, Richard

Volltext

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment von Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean-Jacques

Volltext

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study von Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Rossiev, Viktor, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiri, Yablokova, Vera, Krejcy, Kurt, Grohmann-Izay, Barbara, Hasselbalch, Hans C, Kralovics, Robert, Kiladjian, Jean-Jacques, Bauer, Franz, Berbec, Nicoleta, Besses Raebel, Carlos, Borbenyi, Zita, Bumbea, Horia, Buxhofer-Ausch, Veronika, Calbecka, Malgorzata, Cayssials-Caylus, Emilie, Cazzola, Mario, Cerna, Olga, Cucuianu, Andrei, Dima, Delia Monica, Forjan, Ernst, Gheorghita, Emanuil, Greil, Richard, Hatalova, Antonia, Hrubisko, Mikulas, Jakucs, Janos, Kaplan, Polina, Klymenko, Sergiy, Koschmieder, Steffen, Lazaroiu, Mihaela, Lysa, Tamila, Masliak, Zvenyslava, Masszi, Tamas, Mihaylov, Georgi, Myasnikov, Alexander, Platzbecker, Uwe, Puyade, Mathieu, Rey, Jerome, Roy, Lydia, Schwarz, Jiri, Skotnicki, Aleksander, Sokolova, Irina, Soroka-Wojtaszko, Maria, Starzak-Gwozdz, Jolanta, Stoeva, Vera, Torregrosa-Diaz, Jose Miguel, Vallova, Anna, Volodicheva, Elena, Warzocha, Krzysztof, Willenbacher, Ella, Wolf, Dominik

Volltext

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study (vol 7,... von Gisslinger, H., Klade, C., Georgiev, P.

Volltext

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized,... von Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiri, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean-Jacques

Volltext

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study von SCHULLER, E, JILMA, B, VOICU, V, GOLOR, G, KOLLARITSCH, H, KALTENBÖCK, A, KLADE, C, TAUBER, E

Volltext

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA von Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva‐Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean‐Jacques

Volltext

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension von Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illés, Árpád, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean Jacques

Volltext

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b von Them, Nicole C.C., Bagienski, Klaudia, Berg, Tiina, Gisslinger, Bettina, Schalling, Martin, Chen, Doris, Buxhofer‐Ausch, Veronika, Thaler, Josef, Schloegl, Ernst, Gastl, Guenther A., Wolf, Dominik, Strecker, Karin, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Zagrijtschuk, Oleh, Klade, Christoph, Greil, Richard, Gisslinger, Heinz, Kralovics, Robert

Volltext

S196: ROPEGINTERFERON ALFA‐2B ACHIEVES PATIENT‐SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD‐PV/CONTINUATION‐PV STUDIES von Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva‐Kyuchukova, L., Egyed, M., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Empson, V., Krejcy, K., Hasselbalch, H., Kralovics, R., Kiladjian, J.‐J.

Volltext